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ABSTRACT
Objectives: To determine the relative contribution of
general practices (GPs) to the diagnosis of chlamydia
and gonorrhoea in England and whether treatment
complied with national guidelines.
Design: Analysis of longitudinal electronic health
records in the Clinical Practice Research Datalink
(CPRD) and national sexually transmitted infection
(STI) surveillance databases, England, 2000–2011.
Setting: GPs, and community and specialist STI services.
Participants: Patients diagnosed with chlamydia
(n=1 386 169) and gonorrhoea (n=232 720) at CPRD GPs,
and community and specialist STI Services from
2000–2011.
Main outcome measures: Numbers and rates of
chlamydia and gonorrhoea diagnoses; percentages
of patients diagnosed by GPs relative to other services;
percentage of GP patients treated and antimicrobials used;
percentage of GP patients referred.
Results: The diagnosis rate (95% CI) per 100 000
population of chlamydia in GP increased from 22.8
(22.4–23.2) in 2000 to 29.3 (28.8–29.7) in 2011
(p<0.001), while the proportion treated increased from
59.5% to 78.4% (p=0.001). Over 90% were prescribed
a recommended antimicrobial. Over the same period, the
diagnosis rate (95% CI) per 100 000 population of
gonorrhoea in GP ranged between 3.2 (3–3.3) and
2.4 (2.2–2.5; p=0.607), and the proportion treated ranged
between 32.7% and 53.6% (p=0.262). Despite being
discontinued as a recommended therapy for gonorrhoea in
2005, ciprofloxacin accounted for 42% of prescriptions in
2007 and 20% in 2011. Over the study period, GPs
diagnosed between 9% and 16% of chlamydia cases and
between 6% and 9% of gonorrhoea cases in England.
Conclusions: GP makes an important contribution to
the diagnosis and treatment of bacterial STIs in
England. While most patients diagnosed with chlamydia
were managed appropriately, many of those treated for
gonorrhoea received antimicrobials no longer
recommended for use. Given the global threat of
antimicrobial resistance, GPs should remain abreast of
national treatment guidelines and alert to treatment
failure in their patients.
INTRODUCTION
Chlamydia and gonorrhoea are the two most
commonly diagnosed bacterial sexually trans-
mitted infections (STIs) in the UK, with
237 675 and 28 594 diagnoses, respectively,
reported in 2012.1 Although gonorrhoea is
less prevalent than chlamydia (<0.1% in
women and men aged 16–44 years, vs 1.5%
and 1.1%, respectively, in a recent national
probability survey),2 it can be common in
areas with high concentrations of ‘core
group’ populations, such as men who have
sex with men and persons of black
Caribbean ethnicity.3 4 Infection with these
STIs is usually easily treated with antimicro-
bials but, in the case of gonorrhoea, is com-
plicated by the ability of the infecting
bacterium, Neisseria gonorrhoeae, to develop
Strengths and limitations of this study
▪ This study determined the proportional contribu-
tion and trend in chlamydia and gonorrhoea
diagnoses from general practices (GPs) relative
to other services, and whether these infections
were treated appropriately.
▪ Some double counting of diagnoses of patients
referred to specialist sexually transmitted infec-
tion services is likely.
▪ Diagnoses of chlamydia and gonorrhoea made
outside GP, and made outside community and
specialist services that routinely report to national
surveillance systems, could not be included in our
analysis, but it is likely that the great majority of
diagnoses were captured.
▪ This study provides more complete estimates of
the burden of chlamydia and gonorrhoea diagno-
ses in England.
▪ Most patients diagnosed with chlamydia are
managed appropriately; however, many diag-
nosed with gonorrhoea were treated with antimi-
crobials no longer recommended for use.
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resistance rapidly.5 6 Chlamydial and gonorrhoeal infec-
tion in women is often asymptomatic and may remain
undiagnosed.7 Untreated or inadequately treated infec-
tion can lead to complications such as chronic pelvic
pain, pelvic inﬂammatory disease, ectopic pregnancy
and infertility.8
During the 1990s, the majority of STI diagnoses in
England were made in specialist genitourinary medicine
(GUM) services.9 Since then, primary and community
care services have played an increasingly important role
in the diagnosis of STIs, especially of chlamydia, follow-
ing the introduction of the National Chlamydia
Screening Programme (NCSP) in 2003.10–13 Of those
who do attend GUM clinics, up to 40% may have initially
presented at their general practice (GP).14–16 However,
while screening of asymptomatic infections and testing
of uncomplicated symptomatic infections is appropriate
in non-specialist services, including GPs, referral to spe-
cialist providers for further management and partner
notiﬁcation may sometimes be required to ensure
national standards of care are met.17 18 In particular, as
gonorrhoea can rapidly develop resistance to front-line
therapies, those diagnosed should be referred to special-
ist providers for treatment, test of cure and to perform
culture, in order to avoid inadequate treatment and the
dissemination of resistant or less susceptible strains.17
Despite these signiﬁcant changes in the delivery of
STI services, there is limited recent evidence on the
extent to which STIs are diagnosed, treated and
managed in GP, and on the appropriateness and quality
of care received there.9 19 In this study, we analysed data
from the Clinical Practice Research Datalink (CPRD)
and national STI surveillance databases to estimate the
relative contribution of GP to the diagnosis and treat-
ment of chlamydia and gonorrhoea in England between
2000 and 2011. For those cases diagnosed in GP, we
investigated whether prescriptions to treat chlamydial
and gonococcal infections were issued and, if so,
whether these met standards speciﬁed in respective
national treatment guidelines.
METHODS
Study populations and period
General practice
The CPRD is run by the Medicines and Healthcare
Products Regulatory Agency (MHRA) and collects anon-
ymised patient-level data on all medical, prescription,
investigation/test, immunisation and referral records of
registered patients in a sample of GPs in the UK.20 All
practices use a standard software system to submit data to
the CPRD, which has been extensively used and validated
for public health, epidemiological and pharmacoepide-
miological research, as described elsewhere.21–23 The
CPRD has also been shown to be demographically repre-
sentative of the UK population, with a national coverage
of 6.4% of the population in England, 5.1% in Wales,
2.8% in Scotland and 5.8% in Northern Ireland.24
All registered patients in CPRD practices in England
aged 12–90 years between 1 January 2000 and 31
December 2011 were included in the analysis. Any
records not classiﬁed as ‘up-to-standard’ at practice or
patient level were excluded.20 This is a measure based
on an assessment of completeness, continuity and plausi-
bility of data recording in key areas as regulated by the
CPRD.
GUM clinics
Data from patients attending GUM clinics in England
between 1 January 2000 and 31 December 2011 were
extracted from national surveillance databases held and
managed by Public Health England (PHE): the Korner
Code-60 (KC60) statistical return (2000–2008) and the
GUM clinic activity dataset (GUMCAD; 2009 onwards).25
Form KC60 was a paper-based aggregated statistical
return while GUMCAD collects electronic, disaggregated,
attendance-level data. Reporting of GUM clinic statistical
returns is mandatory and all GUM clinics in England
(209 clinics in 2011) report data every calendar quarter.
Other sexual health services providing chlamydia testing
Data on patients attending for chlamydia testing outside
GUM clinics as part of the NCSP between 1 January
2008 and 31 December 2011 were extracted from aggre-
gated data returns from laboratories reported to PHE.26
Diagnoses of chlamydia and gonorrhoea by service setting
For patients attending GP, attendances for chlamydia
and gonorrhoea were identiﬁed using a predeﬁned
selection of Read codes (see web tables 1 and 2)
included in all medical, referral and test records. Read
codes are assigned at each GP consultation including
any follow-up attendances for a single disease episode.
In order to determine numbers of individual diagnostic
episodes, we assumed an episode length of 42 days
during which duplicate codes were excluded. This was
consistent with previously validated approaches for esti-
mating episode length.19 27
Numbers of chlamydia and gonorrhoea diagnoses
made at GUM clinics were recorded and identiﬁed,
using appropriate KC60, and sexual health and HIV
activity property type (SHHAPT) diagnostic codes.25 For
attendance-level data reported through GUMCAD (ie,
since 2009), the length of individual diagnostic episodes
was deﬁned as for CPRD data (see above). Numbers of
chlamydia diagnoses made by the NCSP were directly
recorded on aggregated NCSP returns. Chlamydia diag-
noses made by GPs through the NCSP were excluded to
avoid double counting.
Prescribing in GP
In CPRD, prescriptions and medical records are not
linked, leading to some ambiguity about the indication
for which a particular prescription is issued, especially
for broad-spectrum antibiotics commonly used to treat
bacterial STIs. For example, prescriptions may be issued
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prior to test results being available and entry of a con-
ﬁrmed diagnosis in the electronic patient record, or for
a concurrent indication unrelated to the STI.
We conducted a sensitivity analysis on a sample
of chlamydia and gonorrhoea records in CPRD from
1 January 2003 to 30 June 2008 to determine the
optimum timeframe for linking prescriptions with diag-
nosis codes. Only recommended treatments during the
study period were used in the sensitivity analysis (doxy-
cycline, azithromycin, erythromycin and oﬂoxacin for
chlamydia, and cephalosporins and ciproﬂoxacin (until
2004) for gonorrhoea). Prescriptions at 0-day, 7-day,
14-day and 30-day intervals on either side of a chlamydia
or gonorrhoea diagnostic code were investigated for the
presence of coindications (see web ﬁgure). A 14-day
interval provided the maximum proportion of treated
STI episodes during which there were no coindications,
and was considered optimum. Compared with including
prescriptions issued only on the date of diagnosis, this
algorithm increased the number of episodes treated by
12% for chlamydia and 3% for gonorrhoea. The sensitiv-
ity of this method was 97.9% and 99.1% for chlamydia
and gonorrhoea, respectively.
To investigate actual prescribing practice, all drugs in
the respective drug classes were included, that is, tetracy-
clines, macrolides, penicillins, cephalosporins and ﬂuor-
oquinolones. Chlamydia and gonorrhoea episodes were
classiﬁed as treated if (1) there were no alternative indi-
cations found within the 14-day interval, or (2) alterna-
tive indications were found but the prescription was
issued on the same date as the STI diagnosis. If more
than one relevant prescription was issued during an
episode, the prescription that was recommended or
issued closest to the diagnosis date was preferred. Any
unusual prescriptions found using the algorithm were
examined manually.
Patient referrals from GP
In CPRD, information on patient referrals can be stored
as Read codes in medical and investigation/test records,
in speciﬁc referral to specialty records, or in unstruc-
tured format in the free text ﬁeld. A patient was deﬁned
as having been referred for further management if any
structured record indicating a referral was found within
the 42-day period of the STI episode. We did not have
access to the free text records, and assumed that most
episodes without a treatment or referral code had likely
been informally referred.19
Count and rate estimates for England
Numbers of diagnostic episodes of chlamydia and gonor-
rhoea within the CPRD population were calculated.
Overall and annual age-standardised and gender-
standardised diagnosis counts and rates (per 100 000
population) with 95% CIs were then estimated for all
GPs in England, using English population estimates.28
Diagnosis counts and rates of chlamydia and gonor-
rhoea in GUM clinics and, for chlamydia, through the
NCSP (excluding GP), were calculated.
Population count and rate estimates in GP were then
expressed as a percentage of total diagnoses and rates in
England. We assumed that all diagnoses made in GP
represented the ﬁrst patient attendance for care, and that
all non-treated episodes had been referred to a specialist
Table 2 Percentage of chlamydia and gonorrhoea episodes by antimicrobial prescribed among general practices included in
the Clinical Practice Research Datalink in England, by year, 2000–2011
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Chlamydia (N) 716 925 994 1088 1219 1196 1145 1471 1446 1453 1374 1130
Azithromycin* 9 11 14 19 21 23 25 32 38 42 49 55
Doxycycline* 38 46 44 42 44 42 44 37 30 26 19 18
Erythromycin* 7 4 5 4 4 4 4 3 4 2 3 3
Ofloxacin* 1 1 1 1 2 2 1 1 1 1 1 1
Other macrolides 1 0 0 0 0 0 0 1 0 0 0 0
Other quinolones 1 0 1 0 0 0 0 0 0 0 0 0
Other tetracyclines 1 1 1 1 1 1 1 0 0 0 0 0
Penicillins 2 2 1 2 1 0 1 1 1 1 1 1
Not treated 41 34 32 30 27 27 25 25 27 28 27 22
Gonorrhoea (N) 101 103 109 135 118 87 85 101 81 117 86 93
Cephalosporins† 3 5 4 1 2 6 12 6 26 14 13 16
Macrolides‡ 3 1 4 1 2 3 6 4 4 3 2 8
Quinolones§ 11 20 19 19 30 22 15 15 17 10 16 9
Tetracyclines 5 9 2 7 4 2 0 3 2 3 2 4
Penicillins 11 3 11 6 8 6 4 3 2 3 8 6
Not treated 67 62 61 67 54 61 64 69 48 67 58 57
Shaded areas represent periods when selected antimicrobial was not recommended in national treatment guidelines.
National Treatment Guidelines.29–31
*Recommended antimicrobial.
†Cefixime and ceftriaxone comprised 79% of the cephalosporins prescribed and cefixime was the recommended therapy from 2005 to 2011.
‡Azithromycin, with ceftriaxone, was recommended for treatment from 2011.
§Ciprofloxacin comprised 92% of the quinolones prescribed and was the recommended therapy until 2004.
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service where a diagnosis would have been recorded and
treated. To avoid double counting when calculating the
percentage of all diagnoses that were made in GP, all non-
treated episodes were therefore excluded from the denom-
inator. The percentage of all episodes that were treated in
GP was calculated in the same way. Tests for linear trend
were performed, and all p values less than 5% were consid-
ered statistically signiﬁcant. Statistical analyses were per-
formed in Microsoft Excel 2010 (Microsoft Corporation,
Redmond, Washington, USA) and Stata V.13.1 (StataCorp
LA, College Station, Texas, USA).
Ethic statement
All GP practices included in the CPRD require consent
from their patients for their anonymised data to be
included in the data set. This protocol to examine STI
trends in CPRD patients was approved by the Independent
Scientiﬁc Advisory Committee of the CPRD. As GUMCAD
and the NCSP are routine public health surveillance activ-
ities, no speciﬁc consent was required from those patients
whose pseudoanonymised (age and limited demographic
data without any patient identiﬁable information) data
were considered in this study. PHE has permission to
handle data obtained from GUMCAD and the NCSP
under section 251 of the UK National Health Service Act
of 2006 (previously section 60 of the Health and Social
Care Act of 2001), which was renewed annually by the
ethics and conﬁdentiality committee of the National
Information Governance Board until 2013. Since then,
the power of approval of public health surveillance activity
has been granted directly to PHE.
RESULTS
Chlamydia
Numbers and rates of diagnoses in GP and other healthcare
settings
Estimated and actual numbers and rates of chlamydia
diagnoses made in GP, the NCSP and GUM clinics
between 2000 and 2011 are presented in table 1 and
web table 3. During the study period, the estimated rate
(95% CI) per 100 000 of chlamydia diagnosis in GP
increased from 22.8 (22.4–23.2) in 2000 to 29.3 (28.8–
29.7) in 2011 (p=0.034). In 2000, 90.5% of episodes in
GP were diagnosed in females (40.3/100 000, 95% CI
39.5 to 41.1) and this decreased to 76% in 2011 (43.8/
100 000, 95% CI 43.1 to 44.7; p value for trend in pro-
portions: 0.001; ﬁgure 1). The diagnosis rate in males
increased from 4.4 (4.2–4.7) in 2000 to 14.3 (13.8–14.7)
in 2011 (ﬁgure 1). During the same period, rates of
diagnoses made in GUM clinics rose from 127.5 to 192.7
per 100 000 (p=0.025), and between 2003 and 2011,
rates of diagnoses made by the NCSP rose from 2.0 to
101.4 per 100 000 (p=0.007). The percentage (95% CI)
of chlamydia diagnoses made in GP relative to other set-
tings decreased from 16.2% (15.9–16.4%) in 2000 to
9.2% (9.1–9.4%) in 2011 (p=0.001).
Prescribing practice in GP
A total of 10 196 episodes of chlamydia were deﬁned as
treated in the CPRD population (after removing 46 fol-
lowing manual review). The percentage (95% CI) of epi-
sodes treated increased from 59.5% (55.8 –63.1%) in 2000
to 78.5% (76.0–80.9%) in 2011 (p=0.012; table 2). Each
Figure 1 Rates of (A) chlamydia and (B) gonorrhoea diagnosed and treated in general practice (GP) clinics included in the
Clinical Practice Research Datalink in England, by gender, 2000–2011.
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year, over 90% of treated episodes were given a BASHH
(British Association for Sexual Health and HIV) recom-
mended regimen (table 2).29 Between 2000 and 2011, use
of azithromycin increased steadily and accounted for
70.6% of treatments in 2011, while doxycycline use
declined from 63.6% to 23.1% (p=0.001). A small number
of non-recommended regimens were identiﬁed, although
this decreased from 7.0% to 1.5% of treatments from 2000
to 2011 (p=0.002). Clarithromycin accounted for all other
macrolides and ciproﬂoxacin for all ﬂuoroquinolones pre-
scribed (there was no evidence of concomitant gonor-
rhoea diagnoses). Amoxicillin can be prescribed in
pregnancy and accounted for 58% of episodes prescribed
penicillins. Of these patients, 18% were pregnant, 33%
were on contraception, 35% had no evidence of preg-
nancy and 14% were male.
Referrals
Only 3% of all chlamydia episodes had a referral
recorded.
Gonorrhoea
Numbers and rates of diagnoses in GP and GUM clinics
Estimated and actual numbers and rates of gonorrhoea
diagnoses made in GP and GUM clinics between 2000
and 2011 are presented in table 1. Between 2000 and
2011, the estimated rate (95% CI) per 100 000 popula-
tion of gonorrhoea diagnosis in GP fell from 3.2 (3–3.3)
in 2000 to 2.4 (2.2–2.5) in 2011 (p=0.018) and the per-
centage of GP diagnoses in women rose from 46.5% to
72.3% (p=0.003; table 1, ﬁgure 1). During the same
period, rates of diagnoses per 100 000 population made
in GUM clinics decreased overall, having ﬂuctuated
from 41.2 in 2000 to 44.9 in 2001, fallen to 29.1 in 2008
then increased to 40.1 in 2001 (p=0.014). The percent-
age (95% CI) of gonorrhoea diagnoses made in GP rela-
tive to GUM clinics ﬂuctuated between 7.5% (7.2–7.9%)
in 2000, 9.1% (8.7–9.6%) in 2009 and 5.7% (5.4–6.1%)
in 2011 (p=0.607).
Prescribing practice in GP
A total of 467 gonorrhoea episodes were deﬁned as
treated in the CPRD population (after removing 44 follow-
ing manual review). The percentage (95% CI) of episodes
treated ﬂuctuated over the 12-year period, increasing from
32.7% (23.7–42.7%) in 2000 to 43.0% (32.8–53.7%) in
2011, with a peak of 51.9% (40.5 –63.1%) in 2008
(p=0.271; table 2). Over the study period, an average of
40% received a recommended regimen each year.30 31
Ciproﬂoxacin (92% of ﬂuoroquinolones prescribed) was
the most commonly prescribed antibiotic (41% of treated
episodes) and continued to be used after the change in
national treatment guidelines favouring cephalosporins in
2005:31 it comprised 42% of prescriptions in 2006 and
2007, decreasing to 20% in 2011 (table 2). Ceﬁxime and
ceftriaxone (79% of cephalosporins prescribed) were
increasingly prescribed from 2005 and were the most
commonly prescribed antibiotics (35%) in 2011.
A high proportion of non-recommended regimens
were prescribed including doxycycline, azithromycin and
other macrolides (erythromycin, clarithromycin), and
penicillin; this proportion ﬂuctuated, decreasing from
67% in 2000 to 39% in 2004, after which it increased to
65% in 2011 (p=0.304). Amoxycillin and ampicillin (42%
of penicillins prescribed) accounted for 90% (28) of
these episodes, of which patients were either male (19%)
or females with no evidence of pregnancy in their record
(32%) or on contraception (39%). Over half (53%) of
prescriptions for other penicillins were for gonococcal
cellulitis.
Referrals
Of the 1216 gonorrhoea episodes, 57 had a referral
record, 29 (51%) of which had also been prescribed an
antimicrobial. An estimated 771 (63%) episodes were
referred to GUM.
DISCUSSION
We present a comprehensive analysis of the management
of chlamydia and gonorrhoea in GP in England since the
turn of the century, against a backdrop of unprecedented
changes in sexual health service provision. We show that
GPs make an important contribution to the diagnosis
and management of these STIs; however, while rates of
chlamydia diagnosed in GP have increased, especially
among males, those of gonorrhoea have been stable or
declined. Prescribing practice has also varied markedly
and, although a greater proportion of GP patients diag-
nosed with either infection are now being treated there,
there is evidence that treatment of a signiﬁcant propor-
tion of gonorrhoea cases used antimicrobials that were no
longer recommended in the national guideline.
Despite the increasing chlamydia diagnosis rates in
GP, the proportional contribution from GP to the total
number of chlamydia diagnoses made in England has
decreased over time to about 9%, coinciding with the
scaling up of the NCSP from 2003 to 2008. There are
now over 200 000 chlamydia diagnoses made each year
in England and over half of these occur in ‘community-
based’ sexual health services such as contraception and
sexual health clinics, as well as GPs.32 The primary aim
of the NCSP is to improve detection and treatment of
chlamydial infection through increased testing of asymp-
tomatic infection, and achieving a chlamydia diagnosis
rate of 2300/100 000 in 15–24-year-olds is now an indicator
in the Public Health Outcomes Framework (PHOF).33
It seems likely that increased chlamydia diagnosis rates in
GP reﬂect the overall drive to improve chlamydia testing
coverage that has occurred in response to the NCSP.
Gonorrhoea diagnoses in GP make up between 5%
and 8% of total diagnoses made in England and the
downward trend in diagnosis rates broadly reﬂects that
seen in GUM clinics during the study period. This sug-
gests there has been minimal change in gonorrhoea
testing practice in GP and that diagnoses mostly follow
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symptomatic presentations. In recent years, dual (chla-
mydia/gonorrhoea) nucleic acid ampliﬁcation tests
(NAATs) are being increasingly used for screening in a
variety of clinical settings.34 Despite their convenience
and increased sensitivity, positive predictive values of
these tests are usually low for gonorrhoea, and conﬁrma-
tory testing is strongly recommended.35 National guide-
lines only recommend asymptomatic gonorrhoea
screening by GPs in high-prevalence areas, and due to
the complexities of management, referral of conﬁrmed
cases to GUM is strongly recommended.35 36 Our study
suggests that under two-thirds of patients diagnosed with
gonorrhoea in GP were referred. If non-attendance fol-
lowing referral is a risk, uncomplicated anogenital infec-
tion can be treated in GP.35 36 However, care pathways
for partner notiﬁcation and test of cure should be in
place, as infection may be a marker that the patient
belongs to a higher risk sexual network.27
Almost 80% of chlamydia episodes in GP in 2011 were
treated, reﬂecting the ongoing, steady increase previ-
ously reported.9 19 Compared with gonorrhoea, patients
with chlamydia were less likely to be referred to GUM
clinics for treatment and, when treated in GP, were most
often prescribed the recommended regimen.9 29 In con-
trast, about 40% of gonorrhoea episodes in GP were
treated, reﬂecting a slight decline since the late 1990s.9
Of greatest concern, however, is that less than half the
patients treated for gonorrhoea in GP were prescribed a
recommended regimen.30 31 Current gonorrhoea treat-
ment guidelines recommend intramuscular administra-
tion of ceftriaxone with concomitant oral azithromycin.30
Recommended antimicrobial treatments should eliminate
infection in at least 95% of cases.37 38 By 2002, 10% of
tested specimens from GUM clinic patients were resistant
to ciproﬂoxacin,39 rising to 36% in 2010.40 Although
ﬂuoroquinolone prescribing in GP fell following the
guidelines changed in 2005, it still accounted for 20% of
prescriptions for gonorrhoea in 2011. In contrast, ﬂuoro-
quinolone prescribing in GUM clinics has declined
rapidly since 2003 and accounted for only 5% of prescrip-
tions in 2010.41 Overall, the most commonly prescribed
non-recommended antibiotic was penicillin, to which up
to 20% of gonorrhoea cases may be resistant.42 While
amoxicillin/ampicillin can be used during pregnancy
there was no evidence of this contributing to the high
proportion of penicillin prescriptions.
Limitations
Some double counting of diagnoses of patients referred
to GUM clinics is likely. We assumed that those treated
in GP were not referred, which may not necessarily be
the case, particularly for gonorrhoea. The proportion
treated was calculated relative to the number of diagno-
ses. Some patients with a negative test result may have
been treated presumptively and these were not included
in our analyses. The number of patients who were
referred to specialist services is likely to be underesti-
mated as we did not have access to free-text information
in CPRD. We were not able to assess whether partner
notiﬁcation was initiated or guidelines followed. Missing
or miscoded medical records in CPRD may explain
some non-recommended treatments.
CPRD data are submitted by a sample of GPs and,
although patients are reasonably representative of the
population, extrapolating numbers of rare and geo-
graphically clustered diagnoses such as gonorrhoea to
provide national estimates may be subject to bias.3 4
Diagnosis of chlamydia and gonorrhoea made outside
GUM, NCSP and GP services could not be included in
our analysis, but it is likely that the great majority of
diagnoses were captured.43
Conclusions and recommendations
Our analysis shows that GPs make an important contri-
bution to the diagnosis and treatment of bacterial STIs
and that most patients diagnosed with chlamydia are
managed appropriately and without the need for
onward referral. While most patients diagnosed with
gonorrhoea by GPs tended to be referred in accordance
with national recommendations, signiﬁcant numbers of
those treated received antimicrobials no longer recom-
mended for use. Treatment of infections with reduced
susceptibility or resistance to the prescribed therapy may
inadvertently facilitate onward transmission and risks
infection complications. GPs may be less aware of gonor-
rhoea treatment guideline revisions due to the relative
infrequency of cases seen.
Our study emphasises the importance of training and
continuing professional development for non-specialists
managing STIs, especially those which require complex
management.36 Antimicrobial resistance in gonorrhoea
is a global problem44 and may become an issue for chla-
mydia in future.45 Practitioners should be alert to the
likelihood of revisions to national treatment guidelines
and of treatment failure in their patients. Ongoing mon-
itoring of diagnoses and treatment of STIs outside GUM
services is essential for estimating the burden of STIs in
the population and to ensure treatments remain appro-
priate and effective.
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